Retatrutide is Eli Lilly's investigational triple agonist, targeting GLP-1, GIP and glucagon receptors. Phase 3 TRIUMPH-1 data (Oct 2026) reported ~30% body-weight loss at 12 mg — the largest observed with any obesity pharmacotherapy. This hub tracks the full program.
Mazdutide, a GLP-1/glucagon dual agonist approved in China in 2025, versus retatrutide, Lilly's GLP-1/GIP/glucagon triple agonist. A side-by-side look at mechanism, trial data, approval status, and population-specific nuances.
Should you actually switch from tirzepatide to retatrutide? A plateau-aware decision framework covering trial data, FDA status, access channels, cost, and side-effect profile — not a how-to protocol.
Alopecia was reported in the Phase 2 retatrutide trial — more often at 8 mg and 12 mg than placebo. Here is what the data actually shows, the telogen effluvium mechanism behind it, and how it compares to semaglutide, tirzepatide, and bariatric surgery.
A head-to-head research comparison of Ozempic (semaglutide) and retatrutide as of early 2026. Covers mechanism, trial-published weight loss, approval status, cost, and the open questions a direct trial has not yet answered.
A step-by-step research walkthrough for reconstituting a lyophilised retatrutide vial with bacteriostatic water. Covers equipment, technique, stability window, labelling, and the most common mistakes.
A research-only walkthrough of the reconstitution math for a 10 mg retatrutide vial. Shows how 1, 2, and 3 mL of bacteriostatic water translate into insulin-syringe units at common research doses, with tradeoffs for each dilution.
A plain-English look at how retatrutide was dosed in the Phase 2 obesity trial and how TRIUMPH-1 titrates to 6 mg or 12 mg maintenance. Includes a week-by-week titration table and a dose-response table from the published NEJM data.
A research-focused review of retatrutide side effects pulled from the NEJM Phase 2 obesity trial and early TRIUMPH Phase 3 readouts. Covers GI tolerability, cardiovascular signals, discontinuation rates, and how the triple agonist stacks up against semaglutide and tirzepatide.
Novo Nordisk's CagriSema combines two peptides — cagrilintide (amylin analogue) and semaglutide (GLP-1) — in a single weekly injection. REDEFINE-1 produced 22.7% body weight loss at 68 weeks, falling short of the 25% target but putting Novo back in the race against Eli Lilly's tirzepatide and retatrutide. Here's the full data.
Eli Lilly's Phase 3 TRIUMPH-1 trial of retatrutide delivered up to 30.3% mean body weight loss at 104 weeks — the highest ever recorded in a pharmacological obesity trial. Here is what the data show, how it compares to tirzepatide and semaglutide, and what it means for the peptide landscape in 2026.
Based on Phase 3 TRIUMPH-1 readouts in Q4 2026, Lilly is expected to file for FDA approval in 2027 with potential first approval in late 2027 or 2028. Timelines may shift as additional TRIUMPH readouts land.
TRIUMPH-1 reported ~30% mean body-weight reduction at the 12 mg dose over 76 weeks in participants with obesity, materially exceeding tirzepatide (~20%) and semaglutide (~15%) at their respective maximum doses.